Thazin Aung, PhD, from Yale School of Medicine, is pioneering an AI-driven tool to enhance melanoma diagnostics by standardizing immune cell evaluations. Traditional assessments by pathologists often result in inconsistent scoring, complicating clinical decision-making. Dr. Aung’s team has focused on improving the reproducibility of these evaluations using AI, which has demonstrated significantly better consistency compared to human assessments. The AI model, trained on thousands of cells and melanoma tissue, shows promise for prospective trials linking immune cell counts to treatment outcomes. While acknowledging the need for pathologists’ expertise, Dr. Aung envisions this tool transforming clinical workflows in dermatopathology, not just for melanoma but for various skin cancers. The future includes developing a dedicated interface for clinical settings, moving beyond open-source software challenges. This breakthrough can significantly aid cancer research and therapeutic decisions, making melanoma treatment more efficient and reliable.
Source link
Share
Read more